Private Equity Portfolio
Aileron Therapeutics Inc.
Joseph A. Yanchik III, Cambridge, MA, US
Aileron Therapeutics is developing the first generation of peptide therapeutics directed at intra-cellular protein-protein interaction targets that are not addressable by current drug modalities. The company’s proprietary cell penetrating “Stapled Peptide” technology is being applied to generate breakthrough therapeutics for the treatment of cancer and other diseases. “Stapled Peptides” have the potential to become a major new class of drugs for intracellular and extracellular targets across therapeutic areas.
Akebia Therapeutics, Inc.
Joseph Gardner, Cincinnati, OH, US
Akebia Therapeutics is developing novel small molecule therapies to ameliorate patient suffering caused by anemia or vascular disease. Akebia's portfolio includes a broad array of enzyme inhibitors that specifically upregulate hypoxia inducible factor (HIF) and angiogenic mechanisms.
Alios BioPharma, Inc.
Lawrence Blatt, San Francisco, CA, US
Alios is discovering and developing novel therapeutic agents based on three platform technologies including: small molecule activators of innate immunity antiviral pathways (RNase L activation), phosphate protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons (Glycoferon). This complementary group of platform technologies has the potential to generate a number of distinct therapeutic products to treat a variety of serious viral infections such as chronic hepatitis B and C, HIV infection, and respiratory viruses (e.g. pandemic influenza) and emerging viral diseases (e.g. SARS).
Ascent Therapeutics Inc.
Frederick Jones, Cambridge, MA, US
Ascent Therapeutics is developing Pepducin™ lipopeptides, novel molecules that exquisitely target the intracellular domains of G protein coupled receptors (GPCRs) to allosterically modulate GPCR signalling. Ascent has programs in oncology, inflammation, cardiovascular and GI disease.
Avila Therapeutics, Inc.
Katrine Bosley, Waltham, MA, US
Avila Therapeutics is a drug discovery company developing a novel proprietary chemistry platform - Avilomics™ - for the generation of new medicines that covalently bond to and silence disease-causing proteins. A pipeline of novel therapeutics is being developed for viral infection, cancer and autommine diseases.